ClinicalTrials.gg
RecruitingNCT07070232Updated Oct 9, 2026

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

A Phase 1/2 interventional study of BNT326 and Pumitamig in Advanced Solid Tumor, sponsored by BioNTech SE. Recruiting at 77 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 9, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,438
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
20th of 1,749
1,438 · median 37
Started
2025
with 61 others
Phase 1/2
287 of 2,049
51 open now
Primary completion
2028-03
later than 299 of 435 live
Registered
1,980th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 20th largest by planned enrollment of the 1,749 interventional ones that give a count, is one of 62 that started in 2025, is one of 287 in phase 1/2, reaches primary completion later than 299 of the 435 other live ones, and was the 1,980th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

Read the detailed description

Both parts (Part 1 and Part 2) will start enrolling study participants independent of each other.

In Part 1, participants with histologically or cytologically confirmed advanced solid tumors will receive BNT326 monotherapy in the following cohorts:

  • Cohort 1A: Cutaneous melanoma (second-line or higher treatment [2L+]).
  • Cohort 1B: Actionable oncogenic alterations (AGA)-negative non-small cell lung cancer (NSCLC) 2L+.
  • Cohort 1C: Epidermal growth factor receptor mutated (EGFRm) NSCLC 2L+.
  • Cohort 1D: Rare melanoma (acral/uveal/mucosal melanoma) 2L+.
  • Cohort 1E: Other advanced solid tumors 2L+.
  • Cohort 1F (drug-drug interaction [DDI] Cohort): Advanced solid tumors.
  • Cohort 1G: Cervical cancer 2L+.

In Part 2, BNT326 will be studied as monotherapy or in combination with other immunotherapeutic agents. The first combination treatment will be BNT326 with BNT327 (also known as pumitamig or PM8002). The following cohorts are planned:

  • Cohort 2A: BNT326 + pumitamig for cutaneous melanoma 2L+.
  • Cohort 2B: BNT326 + pumitamig for human epidermal growth factor receptor 2 (HER2)-negative breast cancer 2L+/first line treatment (1L).
  • Cohort 2C (Optional): BNT326 + pumitamig for cutaneous melanoma first-line or higher treatment (1L+). This cohort may be added if BNT326 + pumitamig for cutaneous melanoma 2L+ is tolerated, and shows signs of efficacy.
  • Cohort 2D: BNT326 + pumitamig for gastric cancer (GC)/gastroesophageal junction cancer (GEJC) 2L+.
  • Cohort 2E: BNT326 + pumitamig for colorectal cancer 2L+.
  • Cohort 2F: BNT326 + pumitamig for cervical cancer 2L+.

Participants in Cohorts 1A, 1B, and 1C (dose optimization cohorts) will be randomized to one of two dose levels (DLs) of BNT326 in a 1:1 ratio. An additional, non-randomized dose level arm (DL3) is included in Cohort 1A.

During the dose randomization phase of Cohorts 2A and 2B, participants will be randomized 1:1 to one of two combination DLs.

During the randomized dose optimization and contribution of components of Cohorts 2D and 2E, participants will be randomized in a 1:1:1 ratio to one of three treatment arms (BNT326 monotherapy at DL2 or BNT326 DL2 with pumitamig [DL1 or DL2] combination treatment). An additional, non-randomized dose level arm is included in Cohorts 2D and 2E (BNT326 DL3 in combination with pumitamig DL1 or DL2).

No randomization is planned for Cohorts 1D, 1E, 1F, 1G, 2C and 2F.

The study will consist of a screening period, a treatment period, a safety follow-up period, an efficacy follow-up period, and a long-term survival follow-up period. Study treatment will be continued for up to 24 months or until disease progression, withdrawal of consent, termination of the study by the sponsor, or unacceptable toxicity. If a participant continues to derive clinical benefit at the end of study, study treatment continuation can be considered case-by-case after discussion with the sponsor's medical monitor. For each participant, the treatment and follow-up periods are projected to be completed within \~38 months (Part 1) and \~48 months (Part 2), unless participants are continuing to benefit from treatment per investigator's recommendation and upon sponsor approval.

03

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Combination with other investigational agents
  • Programmed death-ligand 1 (PD-L1)
  • Antibody-drug conjugate (ADC)
  • Human epidermal growth factor receptor 3 (HER3)
  • Programmed Death-1 (PD-1)
  • Programmed Death-1 monoclonal antibodies
  • Combination chemotherapy
  • Anti vascular endothelial growth factor-A (anti-VEGF-A)
  • Bispecific antibody
  • Immunotherapy
  • Dose optimization
  • Time to progression
  • Vascular endothelial growth factor (VEGF)
  • Cutaneous Melanoma
  • Rare melanoma
  • Actionable oncogenic alterations (AGA)-negative non-small cell lung cancer (NSCLC)
  • Gastric cancer (GC)
  • Gastroesophageal junction cancer (GEJC)
  • Epidermal growth factor receptor mutated (EGFRm) NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria (applicable to all participants and all parts unless otherwise specified):

  • Aged ≥18 years at the time of giving . Local laws will be followed if the age of consent is older.
  • Have histologic or cytologic documented advanced disease, either at relapse or upon diagnosis of disease. This requirement may be considered met when advanced disease derives from unequivocal progression of a previously biopsied site of disease (e.g., progression of residual tumor after concomitant chemo-radiation for Stage III NSCLC).
  • Have defined by v1.1.
  • Have performance status of 0 or 1.
  • Have adequate organ and bone marrow function (as specified in the protocol) within 7 days before randomization/enrollment.
  • Cohort 1A:

    • Have or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.
    • Participants must have previously received a or PD-L1 inhibitor, and, for participants with human gene that encodes a protein called B-Raf (BRAF) gene mutant melanoma, a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene inhibitor with or without mitogen-activated protein kinase protein inhibitor, if available and clinically indicated per local standard of care (SoC) and have experienced progression during or after the previous treatment or discontinued from prior therapy due to intolerance.
  • Cohort 1B and 1C: Have advanced (i.e., metastatic or locally recurrent where local therapy with curative intent is not possible) non-squamous or squamous NSCLC.
  • Cohort 1B:

    • Have no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase rearrangements, or other genomic alterations for which targeted molecular therapies are available. For enrolled participants with predominantly squamous histology tumors, molecular testing will not be required in cases where it is not part of the SoC.
    • Have experienced relapse or progression during or after treatment with standard systemic therapy including platinum-based chemotherapy and/or immune checkpoint inhibitor in the advanced/metastatic setting or discontinued from prior therapy due to intolerance.
    • Participants must have received 1 to 3 in the metastatic setting, which can include anti-PD-1/PD-L1 therapy (if PD-L1 positive), chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently or sequentially. Prior chemotherapy must be limited to 2 lines or less.
  • Cohort 1C:

    • Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).
    • Participants must have received one or two prior lines of systemic therapy for advanced and/or metastatic disease, which must include treatment with an approved EGFR Tyrosine Kinase Inhibitors (TKI), with at least one being a third-generation EGFR TKI. If there is no third-generation EGFR TKI approved as part of SoC by local health authorities in a certain country, failure/progression on any EGFR TKI is acceptable for eligibility.
    • Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1.
    • Prior chemotherapy and amivantamab are permitted only if administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first-line) treatment for advanced/metastatic disease. Participants must not have received any other systemic therapies (such as chemotherapy, immunotherapy, or targeted agents) for advanced/metastatic disease, unless those treatments were given in combination with an EGFR TKI.
    • Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
  • Cohort 1D:

    • Have histologically or cytologically confirmed diagnosis of unresectable or metastatic acral/uveal/mucosal melanoma not amenable to local therapy.
    • Participants must have:

      • Previously been treated with a PD-1 or PD-L1 inhibitor, if clinically indicated and available per local SoC, and/or
      • For participants with Human Leukocyte Antigen Alleles (HLA-A)*02:01 serotype-positive disease (only applicable for uveal melanoma), previously been treated with tebentafusp-tebn if clinically indicated and available per local SoC, and
      • Experienced progression during or after the previous treatment or discontinued from prior therapy due to intolerance.
  • Cohorts 1E and 1F (DDI):

    • Have histologically or cytologically confirmed diagnosis of unresectable or metastatic advanced solid tumor not amenable to ablative or curative approach including, but not limited to:

      • Cholangiocarcinoma, including tumors of the intra- and extrahepatic biliary tract and gallbladder
      • Hepatocellular carcinoma (HCC).
      • Renal cell carcinoma
      • Endometrial carcinoma, excluding those classified as true sarcomas
      • Pancreatic ductal adenocarcinoma (PDAC) (see below other related inclusion criterion)
      • Neuroendocrine tumor of pancreatic, gastrointestinal, lung, and thymus that is well differentiated, Grade 1 to 3.
      • NSCLC (Cohort 1F only)
    • Have experienced disease progression on at least one and no more than three lines of prior therapy or, for Cohort 1E only, discontinued from prior therapy due to intolerance.
    • (For participants with PDAC only) Have received one or two lines of systemic therapy for metastatic tumors, and have experienced progression or intolerance to the treatment during or following therapy.
  • Cohort 2A: Have histologically or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.
  • Cohort 2B: Have histologically or cytologically confirmed diagnosis of recurrent unresectable or metastatic breast cancer that is documented as -negative and either HR-negative or HR-positive per American Society of Clinical Oncology/College of American Pathologists guidelines.
  • Cohort 2D:

    • Histologically and/or cytologically documented metastatic adenocarcinoma and squamous carcinoma of GC/GEJC. (Note: Esophageal squamous-cell carcinoma is excluded).
    • (2L subgroup): Had disease progression during or after one prior line of anti-cancer therapy for recurrent/metastatic disease.
    • (3L subgroup): Has received two or more lines of prior anti-cancer therapy for recurrent/metastatic disease.
    • (HER2-expression positive subgroup): Has received at least one prior line of systemic therapy for recurrent or metastatic disease, including a HER2-targeted agent in accordance with local SoC.
  • Cohort 2E:

    • Histologically and/or cytologically documented recurrent unresectable metastatic colorectal adenocarcinoma.
    • Must have received at least one line to a maximum of three lines of prior SoC treatment for recurrent/metastatic disease.
  • Cohort 1G and 2F:

    • Histologically and/or cytologically documented recurrent unresectable metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology.
    • Must have received platinum-based chemotherapy, with or without an anti-PD-(L)1 agent and bevacizumab for metastatic/recurrent disease, unless the patient is not a candidate in the opinion of the treating physician.

Key Exclusion Criteria (applicable to all participants and all parts unless otherwise specified):

  • Have a history of intolerance to treatment with a topoisomerase I inhibitor or intolerance to an ADC that consists of a topoisomerase I inhibitor, including but not limited to topotecan, irinotecan, and deruxtecan (e.g., severe diarrhea).
  • Have an uncontrolled concomitant or intercurrent illness that contra-indicates study participation, limits compliance with study procedures or substantially increases the risk of incurring adverse events, including:

    • Bleeding diathesis or active hemorrhage,
    • Active infection,
    • class B or C cirrhosis,
    • Known pulmonary disease with significant impact in lung function
    • Oncologic emergencies or complications (e.g., malignant hypercalcemia, superior vena cava syndrome, carcinoid syndrome that is unstable and with available alternative therapies),
    • Psychiatric or abuse condition
    • Infectious colitis Grade ≥2 not resolved to Grade 1 within 72 hours within the past 3 months.
  • Have \<50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment.
  • Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment.
  • Have a history of (non-infectious) interstitial lung disease (ILD) /pneumonitis that required , have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Asymptomatic interstitial changes caused by previous radiation therapy, chemotherapy, or other factors such as smoking are acceptable.
  • Are a participant of who are pregnant or breastfeeding or are planning pregnancy within 225 days (\~7.5 months) after receiving last dose of BNT326 and within 6 months after last dose of pumitamig, whichever is longer.
  • Are potentially fertile males, who are planning to father children during the study or within 135 days (\~4.5 months) after the last dose of BNT326 and within 6 months after last dose of pumitamig, whichever is longer.
  • Are subject to exclusion periods from another study.
  • Specific to pumitamig: Participants with significant risks of hemorrhage or evidence of major coagulation disorders as specified in the protocol.
  • Specific to pumitamig: Have a history of intolerance to treatment with an anti-vascular endothelial growth factor, anti-PD-1/PDL-1, or similar substance, including, but not limited to, bevacizumab, ramucirumab, atezolizumab, pembrolizumab, nivolumab, or other related therapies.
  • Cohort 1E: Have histological diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,438 participants (estimated)

Study arms

  • Experimental
    Part 1 (Cohort 1A) - BNT326 monotherapy

    BNT326 (DL1 or DL2 or DL3) in participants with cutaneous melanoma 2L+

    Drug: BNT326

  • Experimental
    Part 1 (Cohort 1B) - BNT326 monotherapy

    BNT326 (DL1 or DL2) in participants with NSCLC 2L+ AGA-negative

    Drug: BNT326

  • Experimental
    Part 1 (Cohort 1C) - BNT326 monotherapy

    BNT326 (DL1 or DL2) in participants with NSCLC 2L+ EGFRm

    Drug: BNT326

  • Experimental
    Part 1 (Cohort 1D) - BNT326 monotherapy

    BNT326 (DL2 or DL3) in participants with rare melanoma 2L+

    Drug: BNT326

  • Experimental
    Part 1 (Cohort 1E) - BNT326 monotherapy

    BNT326 (DL2) in participants with advanced solid tumors 2L+

    Drug: BNT326

  • Experimental
    Part 1 (Cohort 1F, DDI) - BNT326 + itraconazole

    BNT326 (DL1 or DL2 or DL3) + itraconazole in participants with advanced solid tumors

    Drug: BNT326 · Drug: Itraconazole

  • Experimental
    Part 1 (Cohort 1F, DDI) - BNT326 + paroxetine

    BNT326 (DL1 or DL2 or DL3) + paroxetine in participants with advanced solid tumors

    Drug: BNT326 · Drug: Paroxetine

  • Experimental
    Part 1 (Cohort 1G) - BNT326 monotherapy

    BNT326 (DL2 or DL3) in participants with cervical cancer 2L+

    Drug: BNT326

  • Experimental
    Part 2 (Cohort 2A dose escalation) - BNT326 + pumitamig

    Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2A dose randomization/expansion) - BNT326 + pumitamig

    Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2B dose escalation) - BNT326 + pumitamig

    Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2B dose randomization/expansion) - BNT326 + pumitamig

    Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2C) - Optional - BNT326 + pumitamig

    Combination therapy of BNT326 + pumitamig in participants with cutaneous melanoma 1L+

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2D1) - BNT326 monotherapy

    BNT326 (DL2) in participants with GC/GEJC 2L+

    Drug: BNT326

  • Experimental
    Part 2 (Cohort 2D2) - BNT326 + pumitamig

    Combination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with GC/GEJC 2L+

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2E1) - BNT326 monotherapy

    BNT326 (DL2) in participants with colorectal cancer 2L+

    Drug: BNT326

  • Experimental
    Part 2 (Cohort 2E2) - BNT326 + pumitamig

    Combination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with colorectal cancer 2L+

    Drug: BNT326 · Drug: Pumitamig

  • Experimental
    Part 2 (Cohort 2F) - BNT326 + pumitamig

    Combination therapy of BNT326 with pumitamig in participants with cervical cancer 2L+ (BNT326 DL2 with pumitamig DL1 or DL2 or BNT326 DL3 with pumitamig DL1 or DL2)

    Drug: BNT326 · Drug: Pumitamig

Interventions

  • DrugBNT326

    Intravenous (IV) infusion

  • IV infusion

    Also known as: BNT327, PM8002

  • DrugItraconazole

    Oral administration

  • Oral administration

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)

    By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).

    Time frame: from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)

  2. Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs

    By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2)

    Time frame: from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)

  3. Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)

    Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) based on the investigator's assessment (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) is observed as best overall response. By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  4. Part 2 - Occurrence of dose limiting toxicities (DLTs)

    During the DLT observation period.

    Time frame: from the time of initiation of the first dose of IMP up to 21 days

  5. Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 ADC and unconjugated payload

    Evaluation of Cmax without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.

    Time frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose

  6. Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 ADC and unconjugated payload

    Evaluation of AUC over the last 17-day dosing interval without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.

    Time frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose

Secondary outcomes

  1. Part 1 - Cohort 1F (DDI) only - Occurrence of TEAEs, TRAEs, TESAEs, and TRSAEs

    By treatment, with and without itraconazole or paroxetine

    Time frame: from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP

  2. Part 1 - Cohort 1F (DDI) only - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs

    By cohort and dose, with and without itraconazole or paroxetine

    Time frame: from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP

  3. Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for vital signs

    Time frame: from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP

  4. Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for clinical laboratory tests

    Time frame: from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP

  5. Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for cardiac function

    Assessments comprise 12-lead electrocardiogram (ECG), echocardiography (ECHO) Multi-gated acquisition (MUGA) (scanning) and left ventricular ejection fraction (LVEF).

    Time frame: from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP

  6. Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for Eastern Cooperative Oncology Group performance status (ECOG PS)

    The ECOG PS grades are: 0 = Fully active, able to carry on all pre-disease performance without restriction, 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work, 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours, 3 = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours, 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair, 5 = Dead.

    Time frame: from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP

  7. Parts 1 and 2 - All cohorts - Progression-free survival based on investigator's assessment

    Defined as the time from first dose of IMP to the first objective tumor progression (progressive disease \[PD\] per RECIST v1.1) or death from any cause, whichever occurs first. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  8. Parts 1 and 2 - All cohorts - Depth of response

    Defined as the maximum percent reduction from baseline in tumor size measured by sum of target lesion diameter. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  9. Parts 1 and 2 - All cohorts - Disease control rate

    Defined as the proportion of participants with a confirmed CR, PR, or stable disease (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  10. Parts 1 and 2 - All cohorts - Duration of response

    Defined as the time from first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (PD per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  11. Parts 1 and 2 - All cohorts - Time to response

    Defined as the time from first dose of IMP to first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment). By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  12. Parts 1 and 2 - All cohorts - Overall survival

    Defined as the time from first dose of IMP to death from any cause. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).

    Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

  13. Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Cmax derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload

    For applicable participants, if data permits. By cohort and combination treatment regimen.

    Time frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)

  14. Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: AUC derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload

    For applicable participants, if data permits. By cohort and combination treatment regimen.

    Time frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)

  15. Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload

    For applicable participants, if data permits. By cohort and combination treatment regimen.

    Time frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)

  16. Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload

    For applicable participants, if data permits. By cohort and combination treatment regimen.

    Time frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)

  17. Parts 1 and 2 - All cohorts - Anti-drug antibody (ADA) prevalence and ADA incidence

    For applicable participants. By cohort and combination treatment regimen (against BNT326 and/or pumitamig, as applicable).

    Time frame: up to 1 year from the last dose of IMP

07

Study locations

70 of 77 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's planned 31 months is below that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 17, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Peninsula and South Eastern Haematology & Oncology Group · Frankston, AustraliaNot yet recruiting→Recruiting
  • Hubei Cancer Hospital · Wuhan, ChinaNot yet recruiting→Recruiting
  • Charité - Campus Charité Mitte · Berlin, GermanyNot yet recruiting→Recruiting
  • IRCCS Ospedale San Raffaele Oncologia Medica · Milan, ItalyNot yet recruiting→Recruiting
Show site
  • Chongqing University Cancer Hospital · Chongqing, China
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Peninsula and South Eastern Haematology & Oncology Group · Frankston, AustraliaNot yet recruiting→Recruiting
    • Hubei Cancer Hospital · Wuhan, ChinaNot yet recruiting→Recruiting
    • Charité - Campus Charité Mitte · Berlin, GermanyNot yet recruiting→Recruiting
    • IRCCS Ospedale San Raffaele Oncologia Medica · Milan, ItalyNot yet recruiting→Recruiting
    Show site
    • Chongqing University Cancer Hospital · Chongqing, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07070232
Lead sponsor
BioNTech SE
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Aug 12, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beruzatatug pelitecan · Pumitamig

Start the discussion